EcoDrugPlus

Adrenoceptor Alpha 2a

Ensembl ID : ENSACLG00000016393
Gene Symbol: ADRA2A
1 Cross references
160 Possible Orthologues:

Adrenoceptor Alpha 2c

Ensembl ID : ENSACLG00000004039
Gene Symbol: ADRA2C
2 Cross references
156 Possible Orthologues:

Adrenoceptor Alpha 2c

Ensembl ID : ENSACLG00000014448
Gene Symbol: ADRA2C
1 Cross references
162 Possible Orthologues:

Adrenoceptor Beta 1

Ensembl ID : ENSACLG00000014266
Gene Symbol: ADRB1
3 Cross references
163 Possible Orthologues:

Adrenoceptor Beta 2

Ensembl ID : ENSACLG00000008511
Gene Symbol: ADRB2
3 Cross references
168 Possible Orthologues:

Aldose Reductase-Like

Ensembl ID : ENSACLG00000001828
Gene Symbol: LOC113009224
3 Cross references
348 Possible Orthologues:

Aldose Reductase-Like

Ensembl ID : ENSACLG00000001787
Gene Symbol: LOC113009040
3 Cross references
350 Possible Orthologues:

Alpha Glucosidase

Ensembl ID : ENSACLG00000027927
Gene Symbol: GAA
3 Cross references
233 Possible Orthologues:

Alpha-2a Adrenergic Receptor-Like

Ensembl ID : ENSACLG00000025732
Gene Symbol: LOC113019601
3 Cross references
175 Possible Orthologues:

Alpha-2a Adrenergic Receptor-Like

Ensembl ID : ENSACLG00000027995
Gene Symbol: LOC113019601
3 Cross references
175 Possible Orthologues:

Alpha-2b Adrenergic Receptor-Like

Ensembl ID : ENSACLG00000011940
Gene Symbol: LOC113034174
3 Cross references
175 Possible Orthologues:

Alpha-Synuclein-Like

Ensembl ID : ENSACLG00000007031
Gene Symbol: LOC113025649
2 Cross references
189 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).